FOLH1 and prostate cancer: Preclinical trials employing mouse xenograft models of prostate cancer have demonstrated that this technique effectively sustains BiTE plasma concentration and enhances tumor growth inhibition, especially in tumors exhibiting low PSMA expression [80,86].